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Shih Hann Su,1,2 Valerie Martel-Laferriere,2 Annie-Claude Labbe,2,3
David R. Snydman,1 David Kent,1 Michel Laverdiere,2,3 Claire Beliveau,2,3 Tanya Logvinenko,1
Sandra Cohen,2,4 Silvy Lachance,2,4 Thomas Kiss,2,4 Jean Roy2,4Although the use of nonmyeloablative (NMA) hematopoietic stem cell transplantation (HSCT) regimens has
expanded in the past decade, little data exist to support antiviral prophylaxis to prevent herpes zoster (HZ)
in recipients who are seropositive for varicella-zoster virus in this population. The present study examined
the clinical features, incidence, and risk factors for HZ in a homogeneous cohort of NMA allogeneic HSCT
recipients. We conducted a retrospective cohort study assessing all patients who underwent sibling NMA
HSCTat Maisonneuve-Rosemont Hospital (Montreal) between July 2000 and December 2008. All patients
received the same conditioning regimen, immunoprophylaxis, and graft-versus-host disease therapy. The di-
agnosis of HZ was defined clinically. Factors associated with HZ were identified using a Cox proportional
hazards model. A total of 179 patients were followed for a median of 33 months (interquartile range,
21-59). HZ developed in 66 patients (37%) at a median of 8.3 months post-HSCT; the incidence rate was
175 cases/1000 person-years. The estimated cumulative HZ incidence was 27% at 1 year, 36% at 2 years,
and 44% at 3 years. Thoracic dermatomes were most frequently involved (30%); dissemination occurred
in 5 patients. No deaths resulted from HZ, but 23% of patients developed postherpetic neuralgia. In multi-
variate analysis, reactivation of cytomegalovirus and herpes simplex virus was associated with a reduced like-
lihood of HZ (hazard ratio, 0.54 and 0.33, respectively). Antiviral prophylaxis or treatment for
cytomegalovirus and herpes simplex virus reactivations were protective against HZ. The incidence of HZ
in our cohort of NMA HSCTrecipients is similar to the incidence reported in HSCTrecipients who received
a myeloablative conditioning regimen. Given the observed high risk, we conclude that recommendations for
antiviral prophylaxis should apply, at least for the first year, to the NMA HSCT population as well.
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Herpes zoster (HZ) results from reactivation of
varicella-zoster virus (VZV) latent in thedorsal rootgan-
glia.Up toone-third of the general populationwill even-
tually developHZ in their lifetime [1]; this percentage is
dramatically higher in immunocompromised patients
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6/j.bbmt.2010.10.025cell transplantation (HSCT) [2]. Indeed, a cumulative
incidence ofHZ exceeding 40% at 3 years after myeloa-
blative HSCT has been reported [3,4]. HZ represents a
substantial public health burden due to the debilitating
complications of HZ (eg, postherpetic neuralgia, HZ
ophthalmicus, granulomatous angiitis, and other
neurologic deficits), the high mortality rate associated
with visceral zoster, and the significant costs
associated with treatment and related complications.
To prevent HZ, recent guidelines (2008-2009)
have endorsed antiviral prophylaxis with acyclovir or
valacyclovir for all VZV-seropositive patients under-
going HSCT [5,6]. However, this recommendation
is based solely on studies conducted in patients
conditioned with myeloablative regimens, [7-9]. In
the past decade, lesstoxic nonmyeloablative (NMA)
regimens have been developed specifically for elderly
and debilitated patients, and their use is growing. In-
deed, the proportion of NMA HSCTs performed in
Europe has risenmarkedly, from\1% of all allogeneic
transplantations before 2000 to 36% in 2007 [10,11].
Biol Blood Marrow Transplant 17:1012-1017, 2011 1013Herpes Zoster in Nonmyeloablative Stem Cell TransplantationSome authors have suggested the possibility of
enhanced immune recovery afterNMAHSCT[12], re-
sulting in a lower incidence of infectious complications
and decreased infection-related mortality [13,14].
However, available studies involving NMA regimens
provide insufficient data regarding HZ; small
cohorts, heterogeneous donor/recipient populations,
and differing NMA protocols limit the ability to
derive robust clinical guidelines from these results.
Given the heterogeneity of NMA regimens, there
have been few comprehensive epidemiologic studies
in patients with NMA HSCT, and the current litera-
ture does not provide a firm empirical base arguing
either for or against the recommendation of routine
antiviral prophylaxis for HZ in this population. The
objectives of the present study were to examine the in-
cidence, clinical presentation, and risk factors for HZ
in a large homogeneous cohort of patients undergoing
NMA HSCT.PATIENTS AND METHODS
Patient Population
All patients who underwent NMAHSCT between
July 2000 and December 2008 at Maisonneuve-
Rosemont Hospital in Montreal, a 725-bed tertiary care
hospital accredited by the Foundation for Accreditation
of Cellular Therapy, were included in this study, with
follow-upup toDecember2009.This prospective cohort
has been described previously [15,16]. Data on infectious
disease outcomes were collected retrospectively using
a structured data collection instrument. The hospital’s
institutional review board approved this study.
Nonmyeloablative Conditioning Regimen
All patients received a NMA conditioning regimen
consisting of fludarabine 30mg/m2 daily and cyclophos-
phamide 300 mg/m2 daily for 5 days, followed by infu-
sion of a minimum of 4  106 CD341 blood stem
cells/kg. Tacrolimus 3 mg twice a day was started on
day -8, adjusted to achieve levels of 10-15 nmol/L, con-
tinued until day150, and then tapered by day1100 or
1180 according to the estimated risk of relapse. Myco-
phenolate mofetil 1000 mg twice a day was started on
day 11 and discontinued on day 150. No patient
received total body irradiation. Immunoglobulins and
granulocyte-colony stimulating factor were not rou-
tinely administered after HSCT. All patients received
a 6/6 HLA-identical transplant from a related donor
and were followed by the same HSCT physicians until
death or loss to follow-up. ThisNMAconditioning reg-
imen protocol was designed for application in an outpa-
tient clinic setting. Acute and chronic graft-versus-host
disease (GVHD) was diagnosed and graded using
established criteria [17-19]. All efforts were made to
obtain a tissue biopsy specimen to confirm diagnosis.Treatment algorithms for GHVD were as described
previously [15,16].
Antiviral Prophylaxis and Clinical Events
All candidates for HSCT who were seropositive
for herpes simplex virus (HSV) were prescribed
acyclovir 200 mg 3 times per day from day -1 until
day 121 or the resolution of neutropenia (whichever
was longer). The duration of our HSV prophylaxis is
shorter than the usual 28 days posttransplantation in
patients undergoing myeloablative HSCT [20] be-
cause of a significantly shorter duration of neutropenia
#0.5  109/L (observed in 80% of recipients; median
duration, 10 days) and complete absence of mucositis
in ourNMApopulation [16]. Cytomegalovirus (CMV)
reactivation was followed according to a preemptive
strategy; candidates seropositive for CMV or receiving
a graft from a CMV-seropositive donor were moni-
tored weekly by quantitative polymerase chain reac-
tion (PCR; COBAS Amplicor CMV Monitor Test;
Roche Molecular Diagnostics, Laval, Quebec, Can-
ada) from day 114 until day 1100. All patients with
a positive CMV PCR result were promptly treated
with ganciclovir 5 mg/kg i.v. or valaganciclovir
900 mg orally twice a day until the PCR result became
negative (a minimum of 2 weeks in all patients), at
which point the dosage was reduced to once a day for
an additional 2 weeks of therapy. Patients with a recur-
rent positive CMV PCR result were retreated using
the same schedule. No antiviral prophylaxis for VZV
was administered during the study period.
HZ infection was defined as typical cutaneous
vesicular lesions on an erythematous base within a der-
matome. Dissemination was defined as involvement in
noncontiguous dermatomes. The diagnosis of HZ was
made clinically with or without confirmatory labora-
tory diagnosis. Postherpetic neuralgia was defined as
pain persisting in the affected area for more than 30
days after the development of rash and necessitating
the use of analgesic medication.
Statistical Analysis
Baseline characteristics of the population and
clinical features of HZ are presented as arithmetic
mean6 standard deviation. The timing of events dur-
ing follow-up is presented as median and interquartile
range because of skewed distributions. The probability
of developing HZ was estimated using the Kaplan-
Meier method. Patients who remained HZ free after
NMA HSCT were censored at the time of their last
follow-up or death. The incidence rate was calculated
based on the total person-time contributed by all pa-
tients. Potential predictor variableswere screenedusing
univariate Cox proportional hazards regression, with
each variable of interest as a single main effect. Vari-
ables that reached a P value of\.15 in the univariate
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tivariate analysis was performed using the Cox propor-
tional hazards model with a stepwise selection to
estimate hazard ratios (HRs) with their accompanying
95% confidence intervals (CIs). Results in the multivar-
iate analysis were determined to be statistically signifi-
cant at a two-tailed P value of\.05. The proportional
hazards assumption was satisfied. Data were analyzed
using SAS version 9.1 (SAS Institute, Cary, NC).
RESULTS
Baseline Patient Characteristics
During the study period, a total of 179 patients un-
derwent NMA HSCT in accordance with a standard-
ized protocol at our hospital. The mean patient age
was 53.7 years (Table 1). The study group was 59%
male, and almost 50% of the transplants were mis-
matched for sex. Most patients (82%) had undergone
a previous autologous HSCT, mainly as part of
a sequential therapy protocol consisting of autologous
HSCT followed by allogeneic NMA HSCT. Multiple
myeloma (51%) and lymphoma (37%) were the most
common baseline diagnoses. Most patients were sero-
positive for HSV (81%) and VZV (93%) at the time of
transplantation.
Follow-Up and Non-HZ Events
Complete information was available for 172 of 179
patients. Of the 7 recipients with missing data, 5 had
been transferred to other centers but were known to
be alive in 2009, and 2 were lost to follow-up (median
follow-up for these 7 subjects, 65.8 months). This
cohort was followed for a median of 33.1 months (in-Table 1. Baseline Characteristics of NMA HSCT Recipients
(n 5 179)
Characteristic
Age at transplantation, years, mean ± SD 53.7 ± 7.6
Male sex, n (%) 105 (58.7)
Donor–recipient sex match, n (%) 93 (52.0)
Previous autologous HSCT, n (%) 146 (81.6)
Baseline diagnosis, n (%)*
Multiple myeloma 92 (51.4)
Lymphoma 67 (37.4)
Leukemia 23 (12.8)
Indication for NMA regimen, n (%)
Age 29 (16.2)
Expected toxicity 28 (15.6)
Sequential transplantation 122 (68.1)
Positive pretransplantation recipient serology, n (%)
CMV 75 (41.9)
HSV 145 (81.0)
VZV 167 (93.3)
Positive pretransplantation CMV donor serology, n (%) 72 (40.2)
Total cells infused  108/kg, mean ± SD 10.5 ± 4.5
CD34 cells infused  106/kg, mean ± SD 7.8 ± 3.9
*Four patients had composite malignancies, including multiple myeloma
and non-Hodgkin lymphoma, multiple myeloma and chronic lymphocytic
leukemia, non-Hodgkin lymphoma and Hodgkin disease, and non-
Hodgkin lymphoma and chronic lymphocytic leukemia.terquartile range, 20.6-58.6 months). As detailed in
Table 2, only 22 patients (12%) developed classical
acute GVHD, but most (79%) experienced chronic
GVHD. More than one-third of recipients had an ep-
isode of HSV reactivation, with the earliest occurring
on day 124. No patient experienced reactivation
during acyclovir therapy. Of note, compliance with
acyclovir therapy was 100%, due to the absence of mu-
cositis and provision of the medication by the hospital.
CMV viremia was detected in 50% of the patients at
risk. Patients with viral reactivation were treated with
an antiviral drug (ie, acyclovir, valacyclovir, or famci-
clovir for HSV and ganciclovir or valganciclovir for
CMV, as defined by the preemptive protocol). Relapse
of malignancy occurred in 52 patients, diagnosed at
a median of 15.1 months after transplantation; 45 pa-
tients died, but none of the deaths was related to HZ.
Incidence and Timing of HZ
Sixty-six patients (37%) developed HZ, for an
incidence rate of 175/1000 person-years. One of the
12 patients with a negative VZV serology before trans-
plantation developed primary varicella infection with
a whole-body distribution of vesicles, confirmed by
viral culture and immunofluorescent staining; this
patient was not considered a case of HZ and was not
included in our analysis. When censoring for HZ,
patients were followed for a median of 19.5 months
(interquartile range, 8.1-34.7 months). All patients
had positive VZV serology at the time of transplanta-
tion. The median time of HZ occurrence was 8.3
months post-HSCT. The probability of HZ increased
steadily with increasing time after HSCT, with cumu-
lative incidences of HZ of 27% at 1 year, 36% at 2
years, and 44% at 3 years (Figure 1).
Clinical Presentation of HZ
Amajority of patients presented with localized dis-
ease, most often involving the thoracic dermatomes
(Table 3). Five patients developed disseminated dis-
ease, but no visceral involvement was noted, and no
deaths were associated with HZ. Most patients (95%)
were treated with antiviral therapy (acyclovir 800 mg
5 times a day, valacyclovir 1000 mg 3 times a day, or
famciclovir 500 mg twice a day) for 7-14 days. Despite
treatment, however, nearly 25%of these patients devel-
oped postherpetic neuralgia. Two patients presented
with a bacterial superinfection, one with cellulitis and
one with external otitis. At the time of HZ occurrence,
82% of the patients were still receiving at least one im-
munosuppressive medication, and 85% had been diag-
nosed with chronic GVHD before the HZ episode.
Factors Associated with HZ
In univariate analyses, we examined various clinical
risk factors considered possibly associated with the
Table 2. Timing of Events During Follow-Up (n 5 179)
n Percentage of Total at Risk* Median Month of Occurrence Interquartile Range, Months
All Events
Acute GVHD 22 12.3 2.3 1.7-3.2
Chronic GVHD 134 78.8 4.9 4.2-5.9
First CMV reactivation 56 50.0 1.6 1.0-2.1
First HSV reactivation 56 38.6 5.6 3.5-8.9
First VZV reactivation (HZ) 66 39.5 8.3 4.2-14.4
Malignancy relapse 52 29.1 15.1 7.9-24.3
Death 45 25.1 20.2 6.9-34.7
Events occurring before HZ
Acute GVHD 21 11.7 2.3 1.7-3.2
Chronic GVHD 134 74.9 4.8 4.2-5.9
First CMV reactivation 53 47.3 1.5 1.0-1.9
First HSV reactivation 50 34.5 5.1 3.2-7.7
Malignancy relapse 37 20.7 13.6 3.1-24.1
Death 36 20.1 19.1 5.5-31.4
*Total at risk:
 For CMV: positive donor or pre-HSCTrecipient serology (n 5 112)
 For HSV: positive pre-HSCTrecipient serology (n 5 145)
 For VZV: positive pre-HSCT recipient serology (n 5 167)
 For all other events, all patients in the cohort are considered at risk (n 5 179)
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malignancy relapse, HSV prophylaxis, CMV reactiva-
tion, and HSV reactivation were associated with HZ
(Table 4). After multivariate analysis, CMV reactiva-
tion (adjusted HR, 0.54; 95% CI, 0.30-0.99), HSV re-
activation (adjustedHR, 0.33; 95%CI, 0.16-0.69), and
malignancy relapse (adjusted HR, 0.13; 95% CI, 0.03-
0.54) were each significantly associated with a reduced
likelihood of developing HZ.Table 3. Clinical Features of Patients with HZ (n 5 66)
Clinical Feature
Age, years, mean ± SD 53.1 ± 8.4
Males, n (%) 39 (59.1)
Immunosuppressive drug therapy, n (%) 54 (81.8)DISCUSSION
In our large cohort of sibling NMA allogeneic
HSCT recipients treated homogeneously, we found
a HZ incidence rate of 175 cases/1000 person-years,
a veryhigh rate comparedwithprevious reports inother
immunocompromised groups, including human im-
munodeficiency virus–positive patients (30-50 cases/
1000 person-years) [21-23] and solid organ transplant
recipients (25-40 cases/1000 person-years) [24,25].Figure 1. Cumulative incidence of HZ after NMA allogeneic
transplantation.However, the cumulative incidences ofHZ seen at 1, 2,
and 3 years in the present study (27%-44%) are similar
to those reported after conventional myeloablative
HSCT [2-4], suggesting that the use of NMA
regimen does not significantly reduce the risk of HZ
in HSCT recipients.
Our results stand in contrast to those reported
in two smaller cohorts of NMA HSCT recipients with
an estimatedHZ incidence of#10%at1 year posttrans-
plantation [26,27]. These differences might be related
to our study’s older population, greater incidence
of thymic atrophy, higher incidence and greater
duration of chronic GVHD, associated exposure toMycophenolate mofetil 31
Tacrolimus 43
Prednisone 35
Cyclosporine A 2
Dermatome involved, n (%)
Ophthalmic 10 (15.1)
Cervical 11 (16.7)
Thoracic 20 (30.3)
Lumbar 11 (16.7)
Sacral 8 (12.1)
Disseminated 5 (7.6)
Unknown 1 (1.5)
Postherpetic neuralgia, n (%) 15 (22.7)
Length of treatment, days, mean ± SD 10.3 ± 5.5
Hospital admission, n (%) 14 (21.2)
Length of hospital stay, days, mean ± SD 3.6 ± 2.3
Events preceding HZ episode, n (%)
Acute GVHD 9 (13.6)
Chronic GVHD 56 (84.8)
CMV reactivation 13 (19.7)
HSV reactivation 8 (12.1)
Malignancy relapse 2 (3.0)
Table 4. Factors Associated with HZ (n 5 179)
Univariate Analysis Multivariate Analysis
Factor HR 95% CI HR 95% CI
Age at transplantation 0.99 0.95-1.02
Male sex 1.00 0.61-1.63
Baseline diagnosis
Multiple myeloma 0.71 0.44-1.16 1.19 0.71-2.02
Lymphoma 1.65 1.02-2.68
Leukemia 1.00 0.45-2.18
Previous autologous HSCT 1.02 0.53-1.95
HSV prophylaxis 0.54 0.30-0.97 0.60 0.32-1.12
Acute GVHD 1.38 0.68-2.80
Chronic GVHD 1.48 0.76-2.91
CMV reactivation 0.52 0.28-0.96 0.54 0.30-0.99
HSV reactivation 0.26 0.13-0.55 0.33 0.16-0.69
Malignancy relapse 0.11 0.03-0.43 0.13 0.03-0.54
1016 Biol Blood Marrow Transplant 17:1012-1017, 2011S. H. Su et al.immunosuppressive drugs, use of shorter-duration acy-
clovir for HSV prophylaxis, and longer follow-up. Of
interest, the low prevalence of disseminated disease
(\10%) in our patients is also at variance with the
20% rate reported previously in myeloablative alloge-
neic and autologous HSCT recipients [4,28], perhaps
indicating a different control of dissemination by cell-
mediated immune responses following NMA HSCT.
European guidelines issued in 2008 [5] and re-
cently endorsed by an international panel of HSCT
experts [6] recommend antiviral prophylaxis for at least
1 year posttransplantation for all VZV-positive re-
cipients, independent of the conditioning regimen
intensity. However, all 3 randomized controlled trials
on which these guidelines were based were conducted
exclusively in recipients of myeloablative conditioning
regimens [7-9]. Our findings provide a basis for
extending this recommendation to NMA HSCT
recipients. The apparent protective effects of viral
(both CMV and HSV) reactivation on HZ provide
further support for this position, given that antiviral
treatment of these episodes with drugs that are also
active against VZV is the most likely mechanism by
which HZ was prevented. This inverse relationship
between HSV reactivation and HZ has been
previously reported in transplant recipients and has
been explained by the use of acyclovir [29]. After ad-
justing for other confounding variables, we see
a 46% reduction in the relative risk of HZ associated
with CMV reactivation, and a 67% reduction in the
relative risk of HZ associated with HSV reactivation.
Relapse of malignancy as a protective factor
against HZ is indeed counterintuitive; it may reflect
a state of reduced immunosuppression with decreased
donor chimerism and reduced risk of GVHD [30].
This paradoxical effect could also be explained in the
context of competing risks; because relapse is associ-
ated with death, and death precludes ensuing HZ, re-
lapse appears to be protective by censoring for death
before HZ can occur.Of note is the lack of significance in our cohort of
two well-reported risk factors for HZ: advanced age
and chronic GVHD. Age is known to increase the
risk of HZ in the general population, presumably
through a waning effect of VZV-specific memory T
cells [31]. However, immunosuppression most likely
overwhelms these smaller age-related effects. As for
chronic GVHD, the underlying concept behind
NMA HSCT is to maintain the very fine balance
between myelotoxicity and immunosuppression to
achieve a graft-versus-tumor effect [32]. The high
overall prevalence of chronic GVHD in our cohort
might have kept us from detecting meaningful differ-
ences between the subjects who developed HZ and
those who did not.
Although we observed few severe complications
and no deaths resulting directly from HZ, it is of con-
cern that in our cohort, with almost no loss to follow-
up monitored by an infection-conscious HSCT team,
20% of the patients required hospital admission and
nearly 25% still presented with postherpetic neuralgia.
In this setting of a debilitating pain syndrome, consid-
eration of antiviral prophylaxis warrants emphasis.
However, the optimal duration of prophylaxis during
persistent immunosuppression (eg, chronic GVHD)
remains amatter of debate, as does the occurrence of re-
bound HZ after discontinuation of acyclovir [33-36].
One-third of our patients will still require immuno-
suppressive therapy at 5 years post-HSCT [16], in-
cluding calcineurin inhibitors that might potentiate
renal toxicity to acyclovir, and the continuous use of
antiviral prophylaxis might lead to significant side
effects. Promising strategies to prevent HZ in long-
term HSCT survivors will most likely involve vaccina-
tion, with immunization potentially restoring T cells
to levels seen in populations at low risk [37].
In summary, we found a high incidence of HZ in-
fection (44%) at 3 years after NMAHSCT in a cohort
that, to the best of our knowledge, is the largest
published to date. Our findings provide support to
the recommendation for universal antiviral prophy-
laxis in all VZV-seropositive HSCT recipients, re-
gardless of the conditioning regimen administered.
Although the retrospective data collection process
could have introduced a bias due to missing informa-
tion, our use of a standardized follow-up form in a pop-
ulation that was highly compliant with follow-up visits
likely offsets this concern. Moreover, hypothetically,
missing information on HZ infection would have led
to an underestimation of HZ incidence, further sup-
porting the argument for antiviral prophylaxis.ACKNOWLEDGMENTS
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